Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

This study is testing whether adding a drug called tucidinostat (a type of HDAC inhibitor that affects how cancer genes are turned on and off) to standard CHOP chemotherapy improves outcomes for people newly diagnosed with a specific subtype of T-cell lymphoma called peripheral T-cell lymphoma with follicular helper T-cell phenotype (PTCL-TFH). **You may be eligible if...** - You are between 18 and 80 years old - You have been newly diagnosed with PTCL-TFH (including angioimmunoblastic T-cell lymphoma or follicular helper T-cell lymphoma) confirmed by biopsy - You have not yet received any treatment for this lymphoma - You are in reasonably good physical condition (ECOG 0–2) - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have already received treatment for this lymphoma - You have another active cancer - Your blood counts or organ function are too low for chemotherapy - You have active infections or severe heart conditions Talk to your doctor to see if this trial is right for you.